Salem Radio Network News Wednesday, November 18, 2026

Health

US FDA approves Sanofi’s genetic disorder drug

Carbonatix Pre-Player Loader

Audio By Carbonatix

Nov 18 (Reuters) – The US FDA on Wednesday approved Sanofi’s oral drug venglustat, making it the first treatment for a type of rare genetic condition that affects the brain and nervous system, the health regulator said.

The drug, branded as Infilbray, was approved for adults and children weighing at least 15 kilograms, or about 33 pounds, with type 3 Gaucher disease, a rare inherited disorder that causes fatty substances to build up in the body and brain.

The approval was based on a late-stage study of 43 patients aged 12 years and older whose symptoms outside the brain and nervous system had been stabilized with enzyme replacement therapy.

Patients who received Infilbray once daily for 52 weeks showed improvement on a combined measure of muscle control, coordination and cognitive function compared with those receiving enzyme replacement therapy every two weeks.

The most commonly reported side effects included gastrointestinal problems and effects on mood.

(Reporting by Kamal Choudhury in Bengaluru and Bhanvi Satija in London; Editing by Sahal Muhammed)

Previous
Next
The Media Line News
X CLOSE